• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

How CAR-T Therapies Are Changing the Treatment Landscape for Hematologic Diseases

by | Feb 22, 2022 | Uncategorized

Source: ASCO Daily News In today’s episode, we hear from Dr. Raghuveer Ranganathan, a clinical instructor in the Division of Hematology and Oncology at the UNC School of Medicine at Chapel Hill. His clinical focus is lymphomas and leukemias, with a specific...

FDA grants orphan drug designation to humanized CAR-T for advanced multiple myeloma

by | Feb 16, 2022 | Uncategorized

Source: Healio News The FDA granted orphan drug designation to CT103A, a chimeric antigen receptor T-cell therapy in development for adults with relapsed or refractory multiple myeloma.CT103A (IASO Biotherapeutics/Innovent Biologics) is an autologous, gene-edited CAR...

Multiple myeloma specialist named inaugural director of blood cancer center

by | Feb 6, 2022 | Uncategorized

Source: Healio News Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.Davies currently serves as director of the clinical myeloma program at Perlmutter Cancer Center and...

Case study highlights Parkinson’s-like toxicity after BCMA-directed CAR T-cell therapy

by | Feb 1, 2022 | Uncategorized

Source: Healio News Clinicians who treat patients with chimeric antigen receptor T cells have become adept at identifying and treating acute neurotoxicity, a common adverse event associated with the therapy.Researchers from Mount Sinai published a case study in Nature...

First Allogeneic RNA Cell Therapy Clinical Trial Begins in Multiple Myeloma

by | Jan 27, 2022 | Uncategorized

Source: Cure Today articles A clinical trial to evaluate Descartes-25, a novel allogeneic RNA cell therapy, for multiple myeloma has officially treated its first patient and is now recruiting in certain locations. Read More

Patients with myeloma may benefit from bortezomib treatment prior to kidney transplant

by | Jan 21, 2022 | Uncategorized

Source: Healio News A small single-center study published in Kidney International Reports suggests giving bortezomib treatment to patients with multiple myeloma prior to a kidney transplantation to ensure best outcomes.However, it is still common for patients with...
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT